In 5-Year Span of FDA Accelerated Approvals in Cancer, 43% Show Confirmatory Clinical Benefit
OncLive,
Fifty-seven percent of drugs granted accelerated approval for a cancer indication showed clinical benefit in confirmatory…
Fifty-seven percent of drugs granted accelerated approval for a cancer indication showed clinical benefit in confirmatory…
MADRID – El predominio generacional de la quimioterapia en el cáncer urotelial avanzado de primera línea terminó con una…
Meeting Coverage > ESMO Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy by Charles Bankhead, Senior Editor…
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple…
This Reading Room is a collaboration between MedPage Today® and: About 50% of patients with locally advanced or metastatic…
Centering discussion on clinical scenarios of urothelial carcinoma, expert oncologists review recent data and discuss how…
Abstract Immune checkpoint inhibitors (ICIs) have made important breakthrough in anti-tumor therapy, however, no single…
After reading this article, you should be able to: Differentiate the types of bladder cancer; Understand the treatment options…
The Food and Drug Administration (FDA) has granted full approval and revised the indication for Keytruda® (pembrolizumab) for…
The Food and Drug Administration (FDA) has granted full approval and revised the indication for Keytruda® (pembrolizumab) for…
The FDA has granted a full approval to pembrolizumab for the treatment of cisplatin-ineligible patients with urothelial cancer…
Adding pembrolizumab to first-line chemotherapy did not significantly prolong progression-free survival (PFS) or overall…
NEW YORK (Reuters Health) - Patients with locally advanced, unresectable, or metastatic urothelial cancer may not derive extra…
Oncology/Hematology > Other Cancers Adding pembrolizumab to cisplatin-based chemotherapy did not improve survival outcomes…